Sangamo Therapeutics Inc (NASDAQ:SGMO) has earned a consensus recommendation of “Buy” from the six research firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $13.50.
SGMO has been the subject of a number of research analyst reports. Cowen restated a “buy” rating on shares of Sangamo Therapeutics in a research note on Monday. Wedbush restated a “hold” rating and issued a $11.00 target price on shares of Sangamo Therapeutics in a research note on Wednesday. BidaskClub upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th. HC Wainwright initiated coverage on Sangamo Therapeutics in a research note on Monday, August 26th. They issued a “buy” rating and a $16.00 target price for the company. Finally, Zacks Investment Research lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th.
Several large investors have recently bought and sold shares of SGMO. BlackRock Inc. grew its position in shares of Sangamo Therapeutics by 13.2% during the 2nd quarter. BlackRock Inc. now owns 9,432,178 shares of the biopharmaceutical company’s stock valued at $101,584,000 after acquiring an additional 1,098,030 shares during the period. Nuveen Asset Management LLC acquired a new stake in Sangamo Therapeutics in the 2nd quarter worth about $8,516,000. Vanguard Group Inc. boosted its holdings in Sangamo Therapeutics by 7.7% in the 2nd quarter. Vanguard Group Inc. now owns 8,309,161 shares of the biopharmaceutical company’s stock worth $89,490,000 after buying an additional 596,573 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Sangamo Therapeutics in the 2nd quarter worth about $4,450,000. Finally, Macquarie Group Ltd. boosted its holdings in Sangamo Therapeutics by 247.8% in the 2nd quarter. Macquarie Group Ltd. now owns 400,000 shares of the biopharmaceutical company’s stock worth $4,308,000 after buying an additional 285,000 shares during the last quarter. Hedge funds and other institutional investors own 70.83% of the company’s stock.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.10. The company had revenue of $21.96 million during the quarter, compared to analyst estimates of $12.16 million. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The firm’s quarterly revenue was down 6.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.13) EPS. On average, sell-side analysts predict that Sangamo Therapeutics will post -1.2 EPS for the current fiscal year.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More: Dogs of the Dow
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.